Horm Metab Res 2008; 40(10): 674-678
DOI: 10.1055/s-2008-1073164
Original Basic

© Georg Thieme Verlag KG Stuttgart · New York

(-)-Epigallocatechin Gallate Inhibits Basic Fibroblast Growth Factor-stimulated Interleukin-6 Synthesis in Osteoblasts

H. Tokuda 1 , 2 , S. Takai 2 , Y. Hanai 1 , 2 , R. Matsushima-Nishiwaki 2 , J. Yamauchi 2 , A. Harada 3 , T. Hosoi 4 , T. Ohta 5 , O. Kozawa 2
  • 1Department of Clinical Laboratory, National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan
  • 2Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu, Japan
  • 3Department of Restorative Medicine, National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan
  • 4Department of Advanced Medicine, National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan
  • 5Department of Internal Medicine, National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology, Obu, Japan
Further Information

Publication History

received 25.05.2007

accepted 15.01.2008

Publication Date:
21 May 2008 (online)

Abstract

We previously showed that basic fibroblast growth factor (FGF-2) activates the mitogen-activated protein (MAP) kinase superfamily in osteoblast-like MC3T3-E1 cells and that p38 MAP kinase functions as a positive regulator in the FGF-2-stimulated synthesis of interleukin-6 (IL-6), a potent bone-resorptive agent, in these cells. In the present study, we investigated the exact mechanism of IL-6 and the effects of (−)-epi-gallocatechin gallate (EGCG), one of the major green tea flavonoids, on the synthesis of IL-6. PD98059, an inhibitor of MEK, but not SP600125, an inhibitor of stress-activated protein kinase/c-Jun N-terminal kinase, suppressed FGF-2-stimulated IL-6 synthesis. EGCG significantly reduced the IL-6 synthesis stimulated by FGF-2 in a dose-dependent manner. EGCG attenuated the FGF-2-induced phosphorylation of p44/p42 MAP kinase and p38 MAP kinase. These results strongly suggest that EGCG inhibits the FGF-2-stimulated synthesis of IL-6 at least partly via suppression of the p44/p42 MAP kinase pathway and the p38 MAP kinase pathway in osteoblasts.

References

  • 1 Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer.  Nature. 1997;  387 561
  • 2 Harbourne JB, Williams CA. Advances in flavonoid research since 1992.  Phytochemistry. 2000;  55 481-504
  • 3 Nijweide PJ, Burger EH, Feyen JHM. Cells of bone: proliferation, differentiation, and humoral regulation.  Physiol Rev. 1986;  66 855-886
  • 4 Delaisse JM, Eeckhout Y, Vaes G. Inhibition of bone resorption in culture by (+)-catechin.  Biochem Pharmacol. 1986;  35 3091-3094
  • 5 Choi E-M, Hwang J-K. Effects of (+)-catechin on the function of osteoblastic cells.  Biol Pharm Bull. 2003;  26 523-526
  • 6 Vali B, Rao LG, El-Sohemy A. Epigallocatechin-3-gallate increases the formation of mineralized bone nodules by human osteoblast-like cells.  J Nutr Biochem. 2007;  18 341-347
  • 7 Tokuda H, Takai S, Matsushima-Nishiwaki R, Akamatsu S, Hanai Y, Hosoi T, Harada A, Ohta T, Kozawa O. (−)-Epigallocatechin gallate enhances prostaglandin F2 α-induced VEGF synthesis via up-regula-ting SAPK/JNK activation in osteoblasts.  J Cell Biochem. 2007;  100 1146-1153
  • 8 Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine.  Adv Immunol. 1993;  54 1-78
  • 9 Heymann D, Rousselle AV. gp130 Cytokine family and bone cells.  Cytokine. 2000;  12 1455-1468
  • 10 Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, FGF-2-alpha/IL-1: interrelations in bone resorption pathophysiology.  Cytokine Growth Factor Rev. 2004;  15 49-60
  • 11 Blair HC, Robinson LJ, Zaidi M. Osteoclast signalling pathways.  Biochem Biophys Res Commun. 2005;  328 728-738
  • 12 Ishimi T, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi Y, Yoshiki S, Matsuda T, Hirano T, Kishimoto T, Suda T. IL-6 is produced by osteoblasts and induces bone resorption.  J Immunol. 1990;  145 3297-3303
  • 13 Helle M, Brakenhoff JPJ, Groot ER De, Aarden LA. Interleukin-6 is involved in interleukin-1-induced activities.  Eur J Immunol. 1988;  18 957-959
  • 14 Littlewood AJ, Russil J, Harvey GR, Hughes DE, Russel RGG, Gowen M. The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro.  Endocrinology. 1991;  129 1513-1520
  • 15 Roodman GD. Interleukin-6: an osteotropic factor?.  J Bone Miner Res. 1992;  7 475-478
  • 16 Kozawa O, Tokuda H, Matsuno H, Uematsu T. Involvement of p38 mitogen-activated protein kinase in basic fibroblast growth factor-induced interleukin-6 synthesis in osteoblasts.  J Cell Biochem. 1999;  74 479-485
  • 17 Kyriakis JM, Avruch J. Mammarian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.  Physiol Rev. 2001;  81 807-869
  • 18 Sudo H, Kodama H, Amagai Y, Yamamoto S, Kasai S. In vivo differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria.  J Cell Biol. 1983;  96 191-198
  • 19 Kozawa O, Suzuki A, Tokuda H, Uematsu T. Prostaglandin F2 α stimulates interleukin-6 via activation of PKC in osteoblast-like cells.  Am J Physiol. 1997;  272 E208-E211
  • 20 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.  Nature. 1970;  227 680-685
  • 21 Kato K, Ito H, Hasegawa K, Inaguma Y, Kozawa O, Asano T. Modulation of the stress-induced synthesis of hsp27 and αB-crystallin by cyclic AMP in C6 glioma cells.  J Neurochem. 1996;  66 946-950
  • 22 Tokuda H, Kozawa O, Uematsu T. Basic fibroblast growth factor stimulates vascular endothelial growth factor synthesis in osteoblasts: divergent regulation by p42/p44 MAP kinase and p38 MAP kinase.  J Bone Miner Res. 2000;  15 2371-2379
  • 23 Tokuda H, Hirade K, Wang X, Oiso Y, Kozawa O. Involvement of SAPK/JNK in basic fibroblast growth factor-induced VEGF release in osteoblasts.  J Endocrinol. 2003;  177 101-107
  • 24 Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD98059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo.  J Biol Chem. 1995;  270 27489-27494
  • 25 Bennett BL, Sasaki DT, Murray BW, O’Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.  Proc Natl Acad Sci USA. 2001;  98 13681-13686
  • 26 Tokuda H, Takai S, Hanai Y, Matsushima-Nishiwaki R, Hosoi T, Harada A, Ohta T, Kozawa O. (−)-Epigallocatechin gallate suppresses endothelin-1-induced interleukin-6 synthesis in osteoblasts: Inhibition of p44/p42 MAP kinase activation.  FEBS Lett. 2007;  581 1311-1316
  • 27 Nakagawa H, Wachi M, Woo JT, Kato M, Kasai S, Takahashi F, Lee IS, Nagai K. Fenton reaction is primarily involved in a mechanism of (−)-epigallocatechin-3-gallate to induce osteoclastic cell death.  Biochem Biophys Res Commun. 2002;  292 94-101
  • 28 Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Kichard-Caudron AS, Pinceau B, Weber P. A single ascending dose study of epigalocatechin gallate in healthy volunteers.  J Int Med Res. 2003;  31 88-101

Correspondence

H. Tokuda

Department of Clinical Laboratory

National Hospital for Geriatric Medicine

National Center for Geriatrics and Gerontology

Obu

Aichi 474-8511

Japan

Fax: +81/562/46 83 96

Email: tokuda@ncgg.go.jp

    >